Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
Executive Summary
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
You may also be interested in...
Psychedelic Supply Chain: New Business Models Anticipate Future Demand
Prescription psychedelic drugs in development, and supply for the growing recreational and medicinal use markets globally, are creating new business opportunities in mental health.
New Funding Nectar For Hummingbird As It Progresses Novel Antibodies
Singapore- and US-based rational antibody design venture closes major new financing to support progress of its novel pipeline, with its two lead assets set to enter the clinic shortly. CEO Piers Ingram talks to Scrip about plans and strategy.
Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy
Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.